

2026 Regular Session

HOUSE RESOLUTION NO. 174

BY REPRESENTATIVE OWEN

DRUGS/TESTING: Requests the state surgeon general and the Louisiana Department of Health to assess the feasibility of advancing fenbendazole for potential human use in cancer treatment and to provide guidance on engaging federal authorities for expedited evaluation while protecting public health

1 A RESOLUTION

2 To urge and request the surgeon general and the Louisiana Department of Health to conduct  
3 a professional assessment of fenbendazole as a potential treatment for cancer or other  
4 medical conditions, to evaluate state-level options for supporting further review, and  
5 to develop guidance on engaging the United States Food and Drug Administration  
6 for compassionate use, expanded access programs, or prioritized clinical trials, while  
7 maintaining rigorous patient safety and evidence-based standards.

8 WHEREAS, there is growing public interest in fenbendazole, a veterinary  
9 anthelmintic drug, due to an increasing number of anecdotal reports and patient testimonials  
10 from across the United States, including Louisiana, describing significant recoveries or  
11 remissions from various types of cancer after self-administration, often in conjunction with  
12 other therapies; and

13 WHEREAS, preclinical studies have indicated that fenbendazole may possess  
14 anti-tumor properties, such as disrupting microtubules in cancer cells and inhibiting tumor  
15 growth in laboratory models; and

16 WHEREAS, despite these preliminary findings, fenbendazole is not currently  
17 approved by the United States Food and Drug Administration for human use, and clinical  
18 evidence in humans remains limited to case reports and observational data without  
19 large-scale randomized controlled trials; and

1           WHEREAS, organizations such as the American Cancer Society have cautioned  
2 against the off-label use of fenbendazole outside of controlled clinical settings due to  
3 potential risks, including liver inflammation, and unknown drug interactions; and

4           WHEREAS, the experiences of the COVID-19 pandemic have highlighted the value  
5 of considering innovative and nontraditional treatment options during times of urgent  
6 medical need, prompting many, including members of the Louisiana House of  
7 Representatives, to approach emerging therapies with a more open perspective, while still  
8 prioritizing patient safety; and

9           WHEREAS, rising cancer rates in Louisiana, and reports of residents seeking  
10 unverified sources of fenbendazole, raise important public health considerations that warrant  
11 formal evaluation by the state's chief health officer; and

12           WHEREAS, the expertise of the state surgeon general in public health policy and  
13 emerging therapies is essential to determining whether fenbendazole could offer a viable,  
14 expedited treatment option for patients facing limited alternatives.

15           THEREFORE, BE IT RESOLVED that the House of Representatives of the  
16 Legislature of Louisiana does hereby urge and request the surgeon general of this state to do  
17 all of the following:

18           (1) Provide a professional assessment and guidance regarding the feasibility of  
19 advancing fenbendazole toward potential human authorization for the treatment of cancer  
20 or other medical conditions, including any appropriate state-level steps this state could take  
21 to support, or advocate for, further scientific review.

22           (2) Develop a recommended plan for engaging federal authorities, including the  
23 United States Food and Drug Administration, to expedite evaluation of fenbendazole through  
24 compassionate use protocols, expanded access programs, or prioritization in clinical trials,  
25 while ensuring patient safety and adherence to evidence-based standards.

26           (3) Submit a written report of findings and recommendations to the House  
27 Committee on Health and Welfare no later than February 1, 2027.

28           BE IT FURTHER RESOLVED that a copy of this Resolution be transmitted to the  
29 surgeon general of this state and the secretary of the Louisiana Department of Health.

DIGEST

The digest printed below was prepared by House Legislative Services. It constitutes no part of the legislative instrument. The keyword, one-liner, abstract, and digest do not constitute part of the law or proof or indicia of legislative intent. [R.S. 1:13(B) and 24:177(E)]

---

HR 174 Engrossed

2026 Regular Session

Owen

Requests that the La. Dept. of Health and the state surgeon general study the feasibility of fenbendazole as a treatment for certain health conditions.